Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125506911 | 12550691 | 1 | I | 20160707 | 20160712 | 20160712 | EXP | US-BAUSCH-BL-2016-016606 | BAUSCH AND LOMB | LAWITZ E, POORDAD F, WELLS J, HYLAND R, YANG Y, DVORY-SOBOL H, STAMM L, BRAINARD D, MCHUTCHISON J, LANDAVERDE C, GUTIERREZ J. HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 WITH OR WITHOUT RIBAVIRIN FOR 12 WEEKS IN DIRECT-ACTING ANTIVIRAL-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION. THE INTERNATIONAL LIVER CONGRESS. 2016;. | 61.00 | YR | Y | 0.00000 | 20160712 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125506911 | 12550691 | 1 | PS | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 18859 | ||||||||||
125506911 | 12550691 | 2 | SS | SOFOSBUVIR | SOFOSBUVIR | 1 | Oral | U | 0 | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125506911 | 12550691 | 1 | Hepatitis C |
125506911 | 12550691 | 2 | Hepatitis C |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125506911 | 12550691 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125506911 | 12550691 | Hepatitis C |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |